ABSTRACT -Dopa-responsive dystonia (DRD) is an inherited metabolic disorder now classified as DYT5 with two different biochemical defects: autosomal dominant GTP cyclohydrolase 1 (GCH1) deficiency or autosomal recessive tyrosine hydroxylase deficiency. We report the case of a 10-years-old girl with progressive generalized dystonia and gait disorder who presented dramatic response to levodopa. The phenylalanine to tyrosine ratio was significantly higher after phenylalanine loading test. This condition had two different heterozygous mutations in the GCH1 gene: the previously reported P23L mutation and a new Q182E mutation. The characteristics of the DRD and the molecular genetic findings are discussed.
Hereditary progressive dystonia with marked diurnal fl uctuation or Segawa's disease (OMIM: #128230) is an inherited form of dopa-responsive dystonia (DRD), classifi ed as an autosomal dominant metabolic disorder that results in dopamine defi ciency in the basal ganglia [1] [2] [3] [4] . The incidence is estimated to be between 0.5 and 1 per million people and the typical clinical picture includes onset in childhood, early foot dystonia with progression to multifocal or generalized dystonia, diurnal fl uctuation and dramatic response to levodopa (L-dopa) [1] [2] [3] . It is caused by mutation in the guanosine triphosphate (GTP) cyclohydrolase 1 (GCH1) [1] [2] [3] 5 . There is also an autosomal recessive form caused by mutation in the tyrosine hydroxylase gene (OMIM: #650407) 3 . This disease was fi rst described in 1971, by Segawa et al, as dystonia with diurnal fl uctuation affecting the gait with a benefi cial therapeutic response to L-dopa [1] [2] [3] [4] [5] . Diagnosis can be based on clinical fi ndings (including dramatic and sustained response to low doses of L-dopa), plasma levels of phenylalanine/tyrosine after an oral phenylalanine load and molecular analysis of GCH1 gene [1] [2] [3] [4] [5] [6] . In this study, we describe a patient with progressive limb dystonia whose molecular analysis revealed two different heterozygous missense mutations of the GCH1 gene, one previously described and a novel one.
CASE
A 10-years-old girl presented with progressive diffi culty in running since the age of three years. Initial observation revealed diffi culty in moving the left upper and lower limbs. At eight years of age she had severe gait diffi culties due to involuntary sustained muscle contractions in the lower limbs, tiptoe pattern during walking (wheelchair bound) and worsening of the symptoms as the day progressed, with relief after sleep. She was the fi rst child affected in the family and was born at term of non-consanguineous parents.
Due to symptoms fl uctuation she was fi rstly diagnosed as myasthenia gravis and received pyridostigmine (300 mg per day) and prednisone (20 mg per day). After eight months, without improvement, she was referred to our hospital and the drugs were gradually withdrawn.
On neurological examination the following neurological features were observed: normal cranial nerves; mild hypotrophy of the quadriceps muscle; muscle strength with score 3 in the upper limbs and 2 in the lower limbs according to the Medical Research Council scale; bradykinesia; rigidity in all limbs; cervical dystonia (anterocollis); distal dystonia in the upper and lower limbs at rest exacerbated by voluntary physical activity; increased deep tendon refl exes; and normal sensation.
Both parents were asymptomatic and normal on examination by two neurologists.
The administration of a low-dose of L-dopa/carbidopa (50/12.5 mg per day) resulted on prompt improvement of anterocollis, rigidity and strength. The dose of L-dopa/carbidopa was then increased (100/25mg per day), but she developed erratic myoclonic jerks affecting upper muscle limbs and trunk and a better result was obtained by L-dopa/carbidopa (35/8.75mg per day) and clonazepan 4mg/day. After 30 days she was walking with assistance and with in 6 months of follow-up she was walking independently.
The laboratorial tests (blood count, biochemistry, hepatic and renal function, coagulation tests and cerebrospinal fl uid) and electroencephalogram were normal.
To determine if phenylalanine metabolism was compromised the plasma levels of phenylalanine and tyrosine were measured at baseline and 1, 2, 4, and 6 hours after an oral phenylalanine load (100 mg/kg). Before loading phenylalanine and tyrosine concentrations were normal, but the phenylalanine levels were higher than control subjects after 1, 2, 4 and 6 hours post-load (Table) . No increase in plasma tyrosine was observed after the phenylalanine load (Table) . The phenylalanine to tyrosine ratio (Table) was signifi cantly higher after four hours post-load (normal: < 7.5).
Genomic DNA was extracted from peripheral blood lymphocytes and all six exons, intron-exon boundaries and 5'UTR-region of the GCH1 gene were amplifi ed separately using the polymerase chain reaction (PCR), according to standard procedures 2, 3 . The fragments were amplifi ed and analyzed by direct sequencing using Big Dye Terminator v1.1 (Applied Biosystems) on a 310 ABI PRISM genetic analyzer. The direct sequence analysis showed a heterozygous C > T mutation at position 68 (c.68 C>T) of the GCH1 gene, leading to an amino acid change from nonpolar proline (P) to nonpolar leucine (L) at position 23 (P23L) and a new heterozygous C > G transition at nucleotide position 544 (c.544 C>G) of the GCH1 gene, producing substitution of the non-charged amino acid glutamine (Q) by negatively charged glutamic acid (E) at position 182 (Q182E) (Fig  1) . The mendelian inheritance was confi rmed in the parents, with the mother being a P23L carrier and the father a Q182E carrier (Fig 2) . Our patient is therefore a compound heterozygote for two mutant alleles in the GCH1 gene: the P23L mutation, of maternal origin, and the Q182E mutation, of paternal origin (Fig 2) . The new Q182E mutation was not found in 100 normal chromosomes. After a follow-up of four years, the patient sustained the excellent response to low doses of levodopa.
All studies were done following informed consent of parents.
DISCUSSION
Genetic studies of autosomal dominant DRD fi rstly revealed linkage to the long arm of chromosome 14 and later showed this to be caused by a heterozygous mutation in the GCH1 gene located on 14q22.1-q22.2 7, 8 . This gene has a high degree of variability, and to date more than 100 different mutations have been identifi ed in the GCH1 coding region 5, 9, 10 . The disease is usually confi rmed by means of biochemical tests, and abnormalities of this gene were only observed in 20 to 87% of patients 2, 8, 9, 11, 12 . GCH1 is responsible for catalyzing the formation of tetrahydrobiopterin (BH4), an essential cofactor of tyrosine hydroxylase, which is the rate-limiting step for dopamine biosynthesis 2, 13, 14 .
Where as, the decrease of neopterin as well as biopterin in cerebrospinal fl uid suggested the decrease of GCH1 enzyme as the cause of DRD 2, 5, 13, 14 .
The main clinical features of dopa-responsive dystonia are onset of dystonia at 4-8 years of age, usually in the lower limbs, causing an abnormal gait, diurnal fl uctuation of signs and symptoms and other associated features such as hyperrefl exia and extensor plantar refl exes, parkinsonian signs (such as mask faces), or tremor [1] [2] [3] [4] [5] 15, 16 . Although diurnal variation is a typical feature of DRD, characterized by worsening of symptoms from day to day and improving after sleep, as in our patient, such marked fl uctuation is present only in half patients with DRD [1] [2] [3] [4] [5] 15 . DRD patients can have a marked intrafamilial variability of the clinical manifestations between affected members of the same family 14, 16 .
Although individuals with DRD never develop hyperphenylalaninemia, a subclinical defect in phenylalanine metabolism caused by partial BH4 defi ciency in the liver can often be detected by the phenylalanine loading test, which analyzes plasma phenylalanineto-tyrosine ratios following an oral phenylalanine load 6 .
In our patient, the phenotype included dystonia after a dramatic response to L-dopa trial, and molecular analysis revealed a compound heterozygosity for two mutations in the GCH1 gene: a previously described mutation of maternal origin (P23L) and a novel mutation of paternal origin (Q182E).
The P23L mutation in the GCH1 allele was previously described in four different families 17, 18 . It is particularly interesting the fact that this sequence change was previously detected in a patient with DRD combined with another mutation, suggesting that P23L could represent a rare polymorphism in the population or, alternatively, that this mutation could only be pathogenic in association with another mutation, as in our case 18 .
The new Q182E mutation that was found in our patient led to the substitution of a neutrally charged amino acid by a negatively charged one, a net charge alteration that can adversely affect the structure and function of the GCH1 gene at critical positions of the amino acid sequence. Another mutation (Q182X) that caused DRD was previously reported in this same amino acid position, highlighting the important functional role of this part of the protein 10 . The Q182E mutation in the paternal allele might be suffi cient to reduce GCH1 activity below a critical threshold, although neither mutation alone was suffi cient to cause disease in either of the carrier parents 18 . These observations agree with the hypothesis that the new mutation, in combination with the other previously described, is responsible for the phenotype in our case.
DRD should be considered in any child who presents with paroxysmal or progressive hypertonia of unknown etiology, and its dramatic response to Ldopa has to be emphasized. Fluctuations in response, increased dose requirements, or long-term adverse effects such as the "on-off" phenomenon have not been described 4, 12, [19] [20] [21] . The detection of the specifi c mutation is important to confi rm the diagnosis, and to provide accurate treatment and genetic counseling to the patients and their family. Treatment of these patients is one of the most satisfying experiences in neurology 4, 19 .
